FNA PARAGON 28 INC

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Paragon 28

, a leading national securities law firm, is investigating potential claims against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSE: FNA) and reminds investors of the November 29, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See .

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that throughout the Class Period defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Paragon 28’s financial statements were misstated; (2) Paragon 28 lacked adequate internal controls and at times understated the extent of the issues with its internal controls; and (3) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

On July 30, 2024, after the market closed, Paragon 28 filed a current report on Form 8-K with the SEC disclosing that "the Company's previously issued audited consolidated financial statements for the fiscal year ended December 31, 2023, contained within the Annual Report on Form 10-K for that year . . . and the unaudited condensed consolidated financial statements contained within the Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023, June 30, 2023, September 30, 2023, and March 31, 2024 should no longer be relied upon due to errors in such financial statements, and therefore a restatement of these prior financial statements is required."

On this news, Paragon 28's stock fell $1.24 per share, or 13.7%, to close at $7.79 per share on July 31, 2024.

Then, on August 8, 2024, the Company issued a press release announcing its financial results for the second quarter of 2024. In it, the Company issued revised full-year revenue guidance of $249 million to $255 million, down from a previous range of $249 million to $259 million. The Company also announced the implementation of an "operational efficiency strategy" that involved a 7% reduction in workforce, an "inventory burn-down", and a "[o]ne-time realignment of executive compensation for 2024."

On this news, Paragon 28's stock fell $1.67 per share, or 20.1%, to close at $6.64 per share on August 9, 2024.

Finally, after the market closed on September 20, 2024, Paragon disclosed the abrupt departure of Defendant Erik Mickelson, the Company’s Chief Accounting Officer.

This news sent the price of Paragon shares down $0.30 (-4.3%) on September 23, 2024.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Paragon 28’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Paragon 28 class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on , on , or on .

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
29/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PARAGON 28 INC

 PRESS RELEASE

Paragon 28 to Feature Several Recent Product Launches at The American ...

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons (“AAOS”). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data a...

 PRESS RELEASE

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter ...

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported growth of approximately 18.0% to 18.5% compared to the fourth quarter of 2023. Preliminary unaudited net revenue for the full year of 2024 is ...

 PRESS RELEASE

Paragon 28 to Present at the 43rd Annual J.P. Morgan Healthcare Confer...

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company’s website at About Paragon 28, Inc. Based in Englewood, C...

 PRESS RELEASE

Paragon 28 Appoints Dave Demski to Board of Directors

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recentl...

 PRESS RELEASE

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...

NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSE: FNA) and reminds investors of the November 29, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the compla...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch